Clinical Trials Directory

Trials / Completed

CompletedNCT05032833

Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects

A Double-Blind, Randomized, Phase 1, First-in-Human, Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of Intranasal 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in Healthy Subjects

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
36 (actual)
Sponsor
Beckley Psytech Limited · Industry
Sex
All
Age
25 Years – 55 Years
Healthy volunteers
Accepted

Summary

The study will evaluate safety, tolerability and PK profile of 5-MeO-DMT in healthy subjects

Conditions

Interventions

TypeNameDescription
DRUG5-MeO-DMTA single dose of 5-MeO-DMT will be administered intranasally
OTHERPlaceboA single dose of placebo will be administered intranasally

Timeline

Start date
2021-09-22
Primary completion
2022-07-07
Completion
2022-07-07
First posted
2021-09-02
Last updated
2022-10-12

Locations

1 site across 1 country: United Kingdom

Source: ClinicalTrials.gov record NCT05032833. Inclusion in this directory is not an endorsement.